Antibody-Drug Conjugates for the Treatment of Cancer

Chemical Biology and Drug Design

Volumn 81, Issue 1, 2013, Pages 113-121

  Flygare, John A ^a   Pillow, Thomas H ^a   Aristoff, Paul ^b  

^a GENENTECH INC   (United States)

^b Aristoff Consulting   (United States)

Author keywords

Antibody drug conjugate; Cytotoxic payload; Linker

Indexed keywords

ALPHA AMANITIN; ANTIMITOTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BRENTUXIMAB VEDOTIN; CALICHEAMICIN; CYTOTOXIC AGENT; DOXORUBICIN; DUOCARMYCIN A; DUOCARMYCIN DERIVATIVE; GEMTUZUMAB OZOGAMICIN; HYDRAZONE DERIVATIVE; INOTUZUMAB OZOGAMICIN; MAYTANSINE; MONOMETHYLAURISTATIN E; N ACETYL GAMMA CALICHEAMICIN; PYRROLOBENZODIAZEPINE DERIVATIVE; RITUXIMAB; SUCCINIMIDYL 4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLATE; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER THERAPY; CONJUGATE; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CROSS-LINKING REAGENTS; HUMANS; IMMUNOCONJUGATES; NEOPLASMS; PHARMACEUTICAL PREPARATIONS;

EID: 84871362496     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12085     Document Type: Article

References (62)

1. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P. et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med;366:883-892.
2. Sapra P., Hooper A.T., O'Donnell C.J., Gerber H.-P. (2011) Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs;20:1131-1149.
3. Polson A.G., Ho W.Y., Ramakrishnan V. (2011) Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs;20:75-85.
4. Carter P.J., Senter P.D. (2008) Antibody-drug conjugates for cancer therapy. Cancer J;14:154-169.
5. Adair J.R., Howard P.W., Hartley J.A., Williams D.G., Chester K.A. (2012) Antibody-drug conjugates - a perfect synergy. Expert Opin Biol Ther;12:1191-1206.
6. Casi G., Neri D. (2012) Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release;161:422-428.
7. Ducry L., Stump B. (2010) Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem;21:5-13.
8. Polakis P. (2005) Arming antibodies for cancer therapy. Curr Opin Pharmacol;5:382-387.
9. Sammet B., Steinkühler C., Sewald N. (2012) Antibody-drug conjugates in tumor therapy, Pharmaceutical patent Analyst. Future Sci;1:65-73.
10. Chari R.V.J. (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res;41:98-107.
11. Ojima I. (2008) Guided molecular missiles for tumor-targeting chemotherapy - case studies using the second-generation taxoids as warheads. Acc Chem Res;41:108-119.
12. Govindan S.V., Goldenberg D.M. (2012) Designing immunoconjugates for cancer therapy. Expert Opin Biol Ther;12:873-890.
13. Milenic D.E., Brechbiel M.W. (2004) Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther;3:361-370.
14. Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E., Blattler W.A. et al. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res;68:9280-9290.
15. Advani A., Coiffier B., Czuczman M.S., Dreyling M., Foran J., Gine E., Gisselbrecht C. et al. (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol;28:2085-2093.
16. Hamann P.R., Hinman L.M., Hollander I., Beyer C.F., Lindh D., Holcomb R., Hallett W., Tsou H.-R., Upeslacis J., Shochat D., Mountain A., Flowers D.A., Bernstein I. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem;13:47-58.
17. Bross P.F., Beitz J., Chen G., Chen X.H., Duffy E., Kieffer L., Roy S., Sridhara R., Rahman A., Williams G., Pazdur R. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res;7:1490-1496.
18. Katz J., Janik J.E., Younes A. (2011) Brentuximab Vedotin (SGN-35). Clin Cancer Res;17:6428-6436.
19. Wang L., Amphlett G., Blättler W.A., Lambert J.M., Zhang W. (2005) Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci;14:2436-2446.
20. Hamblett K.J., Senter P.D., Chace D.F., Sun M.M.C., Lenox J., Cerveny C.G., Kissler K.M., Bernhardt S.X., Kopcha A.K., Zabinski R.F., Meyer D.L., Francisco J.A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res;10:7063-7070.
21. Voynov V., Chennamsetty N., Kayser V., Wallny H.-J., Helk B., Trout B.L. (2010) Design and application of antibody cysteine variants. Bioconjug Chem;21:385-392.
22. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., Chen Y. et al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol;26:925-932.
23. Hollander I., Kunz A., Hamann P.R. (2008) Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug Chem;19:358-361.
24. Burke P.J., Senter P.D., Meyer D.W., Miyamoto J.B., Anderson M., Toki B.E., Manikumar G., Wani M.C., Kroll D.J., Jeffrey S.C. (2009) Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. Bioconjug Chem;20:1242-1250.
25. King H.D., Dubowchik G.M., Mastalerz H., Willner D., Hofstead S.J., Firestone R.A., Lasch S.J., Trail P.A. (2002) Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. J Med Chem;45:4336-4343.
26. King H.D., Yurgaitis D., Willner D., Firestone R.A., Yang M.B., Lasch S.J., Hellström K.E., Trail P.A. (1999) Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: a novel method for increasing the potency of doxorubicin immunoconjugates. Bioconjug Chem;10:279-288.
27. Zhao R.Y., Wilhelm S.D., Audette C., Jones G., Leece B.A., Lazar A.C., Goldmacher V.S., Singh R., Kovtun Y., Widdison W.C., Lambert J.M., Chari R.V.J. (2011) Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem;54:3606-3623.
28. Hitchcock S.A. (2012) Structural modifications that alter the P-glycoprotein efflux properties of compounds. J Med Chem;55:4877-4895.
29. Zhao R.Y., Erickson H.K., Leece B.A., Reid E.E., Goldmacher V.S., Lambert J.M., Chari R.V.J. (2012) Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. J Med Chem;55:766-782.
30. Erickson H.K., Park P.U., Widdison W.C., Kovtun Y.V., Garrett L.M., Hoffman K., Lutz R.J., Goldmacher V.S., Blättler W.A. (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res;66:4426-4433.
31. Erickson H.K., Lewis Phillips G.D., Leipold D.D., Provenzano C.A., Mai E., Johnson H.A., Gunter B., Audette C.A., Gupta M., Pinkas J., Tibbitts J. (2012) The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther;11:1133-1142.
32. Trail P.A., Willner D., Lasch S.J., Henderson A.J., Hofstead S., Casazza A.M., Firestone R.A., Hellström I., Hellström K.E. (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science;261:212-215.
33. Tolcher A.W., Sugarman S., Gelmon K.A., Cohen R., Saleh M., Isaacs C., Young L., Healey D., Onetto N., Slichenmyer W. (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol;17:478-484.
34. van Der Velden V.H., te Marvelde J.G., Hoogeveen P.G., Bernstein I.D., Houtsmuller A.B., Berger M.S., van Dongen J.J. (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood;97:3197-3204.
35. Damle N.K., Frost P. (2003) Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol;3:386-390.
36. DiJoseph J.F., Dougher M.M., Kalyandrug L.B., Armellino D.C., Boghaert E.R., Hamann P.R., Moran J.K., Damle N.K. (2006) Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res;12:242-249.
37. Hamann P.R., Hinman L.M., Beyer C.F., Lindh D., Upeslacis J., Flowers D.A., Bernstein I. (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem;13:40-46.
38. Hamann P.R., Hinman L.M., Beyer C.F., Lindh D., Upeslacis J., Shochat D., Mountain A. (2005) A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. Bioconjug Chem;16:354-360.
39. Lee M.D., Dunne T.S., Siegel M.M., Chang C.C., Morton G.O., Borders D.B. (1987) Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin.gamma.1I. J Am Chem Soc;109:3464-3466.
40. Lee M.D., Dunne T.S., Chang C.C., Ellestad G.A., Siegel M.M., Morton G.O., McGahren W.J., Borders D.B. (1987) Calichemicins, a novel family of antitumor antibiotics. 2. Chemistry and structure of calichemicin.gamma.1I. J Am Chem Soc;109:3466-3468.
41. Ojima I., Geng X., Wu X., Qu C., Borella C.P., Xie H., Wilhelm S.D., Leece B.A., Bartle L.M., Goldmacher V.S., Chari R.V.J. (2002) Tumor-specific novel taxoid-monoclonal antibody conjugates. J Med Chem;45:5620-5623.
42. Widdison W.C., Wilhelm S.D., Cavanagh E.E., Whiteman K.R., Leece B.A., Kovtun Y., Goldmacher V.S., Xie H., Steeves R.M., Lutz R.J., Zhao R., Wang L., Blättler W.A., Chari R.V.J. (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem;49:4392-4408.
43. Xie H., Audette C., Hoffee M., Lambert J.M., Blättler W.A. (2004) Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther;308:1073-1082.
44. Koblinski J.E., Ahram M., Sloane B.F. (2000) Unraveling the role of proteases in cancer. Clin Chim Acta;291:113-135.
45. Dubowchik G.M., Firestone R.A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett;8:3341-3346.
46. Dubowchik G.M., Mosure K., Knipe J.O., Firestone R.A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett;8:3347-3352.
47. Dubowchik G.M., Firestone R.A., Padilla L., Willner D., Hofstead S.J., Mosure K., Knipe J.O., Lasch S.J., Trail P.A. (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem;13:855-869.
48. Blencowe C.A., Russell A.T., Greco F., Hayes W., Thornthwaite D.W. (2011) Self-immolative linkers in polymeric delivery systems. Polym Chem;2:773.
49. DeWit M.A., Gillies E.R. (2011) Design, synthesis, and cyclization of 4-aminobutyric acid derivatives: potential candidates as self-immolative spacers. Org Biomol Chem;9:1846-1854.
50. Toki B.E., Cerveny C.G., Wahl A.F., Senter P.D. (2002) Protease-mediated fragmentation of p-aminobenzyl ethers: a new strategy for the activation of anticancer prodrugs. J Org Chem;67:1866-1872.
51. Schmid K.M., Jensen L., Phillips S.T. (2012) A self-immolative spacer that enables tunable controlled release of phenols under neutral conditions. J Org Chem;77:4363-4374.
52. De Groot F.M.H., Beusker P.H., Scheeren J.W. (2010) Prodrugs built as multiple self-elimination-release spacers. United States Patent, US7705045(B2, X601) 1-128.
53. de Groot F.M.H., Albrecht C., Koekkoek R., Beusker P.H., Scheeren H.W. (2003) "Cascade-release dendrimers" liberate all end groups upon a single triggering event in the dendritic core. Angew Chem Int Ed Engl;42:4490-4494.
54. De Groot F.M.H., Beusker P.H., Scheeren J.W., De Vos D., Van Berkom L.W.A., Busscher G.F., Seelen A.E., Koekkoek R., Albrecht C. (2007) Elongated and multiple spacers in activatable prodrugs. United States Patent, US7223837(B2) 1-37.
55. Chari R.V., Jackel K.A., Bourret L.A., Derr S.M., Tadayoni B.M., Mattocks K.M., Shah S.A., Liu C., Blattler W.A., Goldmacher V.S. (1995) Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res;55:4079-4084.
56. Jeffrey S.C., Nguyen M.T., Moser R.F., Meyer D.L., Miyamoto J.B., Senter P.D. (2007) Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. Bioorg Med Chem Lett;17:2278-2280.
57. Hartley J.A. (2011) The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs;20:733-744.
58. Hartley J.A., Hamaguchi A., Suggitt M., Gregson S.J., Thurston D.E., Howard P.W. (2012) DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2, 1-c][1, 4]benzodiazepine dimer SG2057. Invest New Drugs;30:950-958.
59. Howard P.W., Jeffrey S., Burke P., Senter P. (2011) Targeted pyrrolobenzodiazepine conjugates. International Patent Application, WO2011130613(A1) 1-149.
60. Walton J.D., Hallen-Adams H.E., Luo H. (2010) Ribosomal biosynthesis of the cyclic peptide toxins of Amanita mushrooms. Biopolymers;94:659-664.
61. Moldenhauer G., Salnikov A.V., Luttgau S., Herr I., Anderl J., Faulstich H. (2012) Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst;104:622-634.
62. Hutchins B.M., Kazane S.A., Staflin K., Forsyth J.S., Felding-Habermann B., Smider V.V., Schultz P.G. (2011) Selective formation of covalent protein heterodimers with an unnatural amino acid. Chem Biol;18:299-303.